PubRank

Samia J Khoury

Author PubWeight™ 111.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005 7.80
2 Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A 2004 4.70
3 The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003 4.20
4 CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 2007 3.39
5 IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A 2009 3.31
6 Expression of Cux-1 and Cux-2 in the subventricular zone and upper layers II-IV of the cerebral cortex. J Comp Neurol 2004 3.20
7 Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003 3.00
8 Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A 2008 2.57
9 Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 2012 2.18
10 Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol 2009 2.15
11 A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 2005 2.13
12 Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012 2.11
13 Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex. Nat Genet 2003 1.96
14 Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med 2007 1.93
15 Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 2005 1.89
16 Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest 2003 1.76
17 Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 2009 1.70
18 Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain 2008 1.67
19 Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol 2006 1.54
20 Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler 2013 1.51
21 Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009 1.50
22 Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology 2013 1.46
23 TGF-beta induces IL-9 production from human Th17 cells. J Immunol 2010 1.40
24 Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am J Pathol 2007 1.39
25 Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 2005 1.36
26 Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain 2008 1.34
27 Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing--remitting experimental autoimmune encephalomyelitis. Brain 2007 1.31
28 Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J Neurosci 2006 1.31
29 An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med 2012 1.29
30 Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006 1.26
31 Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity 2012 1.24
32 Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging 2011 1.24
33 JAGGED1 and delta1 differentially regulate the outcome of experimental autoimmune encephalomyelitis. J Immunol 2007 1.23
34 Reversible neural stem cell niche dysfunction in a model of multiple sclerosis. Ann Neurol 2011 1.12
35 Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. Am J Pathol 2004 1.09
36 Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol 2010 1.09
37 Paradoxical dysregulation of the neural stem cell pathway sonic hedgehog-Gli1 in autoimmune encephalomyelitis and multiple sclerosis. Ann Neurol 2008 1.08
38 Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J Immunol 2011 1.07
39 Notch ligand delta-like 4 blockade alleviates experimental autoimmune encephalomyelitis by promoting regulatory T cell development. J Immunol 2011 1.06
40 Immunopathogenesis of multiple sclerosis. Clin Immunol 2011 1.05
41 IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions. J Neuroimmunol 2002 1.05
42 Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol 2006 1.04
43 Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol 2009 1.04
44 Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol 2008 1.03
45 Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis. Physiol Genomics 2003 1.02
46 Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in mice. J Biomed Opt 2011 0.99
47 The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1,249 patients with multiple sclerosis. J Neuroimaging 2011 0.98
48 Immunotherapy for neurological diseases. Clin Immunol 2008 0.97
49 In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 2012 0.95
50 Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol 2008 0.93
51 Stem cells: cross-talk and developmental programs. Philos Trans R Soc Lond B Biol Sci 2004 0.93
52 CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci 2010 0.92
53 Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol 2005 0.89
54 Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis. Immunol Res 2003 0.88
55 Potential application of tregitopes as immunomodulating agents in multiple sclerosis. Neurol Res Int 2011 0.88
56 Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients. J Neuroimmunol 2002 0.88
57 Rate of brain atrophy in benign vs early multiple sclerosis. Arch Neurol 2009 0.88
58 Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. J Allergy Clin Immunol 2003 0.87
59 A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One 2010 0.87
60 Corticotropin-releasing hormone contributes to the peripheral inflammatory response in experimental autoimmune encephalomyelitis. J Immunol 2005 0.86
61 A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 2008 0.85
62 IL-4 and retinoic acid synergistically induce regulatory dendritic cells expressing Aldh1a2. J Immunol 2013 0.85
63 20. Immunologic neuromuscular disorders. J Allergy Clin Immunol 2003 0.85
64 Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci 2011 0.85
65 Th17 and Treg balance in systemic sclerosis. Clin Immunol 2011 0.84
66 Magnetic resonance imaging surrogates of multiple sclerosis pathology and their relationship to central nervous system atrophy. J Neuroimaging 2004 0.83
67 Type17 T-cells in central nervous system autoimmunity and tumors. J Clin Immunol 2012 0.83
68 Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol 2004 0.83
69 Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo. J Immunol 2004 0.81
70 Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis. Clin Immunol 2011 0.81
71 T cell costimulatory pathways: blockade for autoimmunity. Expert Opin Biol Ther 2003 0.81
72 Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters. J Neuroimmunol 2006 0.80
73 Neural stem cells and the future treatment of neurological diseases: raising the standard. Methods Mol Biol 2008 0.80
74 Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs 2002 0.79
75 Subventricular zone microglia transcriptional networks. Brain Behav Immun 2010 0.79
76 Increased Th17 response to myelin peptides in pediatric MS. Clin Immunol 2012 0.78
77 Assessment by flow cytometry of intracellular cytokine production in the peripheral blood cells of renal transplant recipients. Clin Transplant 2004 0.78
78 One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 2011 0.77
79 Modulating co-stimulation. Neurotherapeutics 2007 0.75
80 Sex influences in autoimmune disease. Clin Immunol 2013 0.75
81 Therapeutic strategies in multiple sclerosis. Clin Immunol 2011 0.75